BioT Whitepaper: Empowering Biotechnology Through Decentralized Funding

Version 1.0
June 2025

1.0 Introduction

Biotechnology fuels breakthroughs in healthcare, agriculture, and sustainability, but traditional funding systems—banks, venture capital, grants—create barriers with high fees, opacity, and limited access. BioT, an ERC-20 token on Ethereum, solves this by enabling decentralized, transparent funding for biotech projects. Using smart contracts and trading on Uniswap V2, BioT connects researchers, startups, and investors globally, bypassing intermediaries.

With 485,000,000 tokens (10,000,000 circulating), BioT builds a community-driven ecosystem. This whitepaper details its vision, technology, economics, and roadmap for scalable biotech funding. Contact: ganda314@yahoo.com.

Mission: Democratize biotechnology funding via a secure, accessible blockchain platform.

2.0 Problem Statement

Biotech funding faces critical hurdles:

- Centralized Control: Venture capitalists and banks favor established players, excluding early-stage innovators.
- Lack of Transparency: Opaque fund allocation erodes trust.
- High Fees: Intermediaries take 10-20% of capital, reducing research funds.
- Limited Access: Innovators in underserved regions struggle to secure resources.
- Delays: Bureaucratic funding processes stall time-sensitive projects.

A decentralized, transparent system is needed to empower biotech innovation.

3.0 BioT's Solution

BioT uses Ethereum's blockchain for a decentralized funding platform, offering:

3.1 Smart Contract Funding

Audited smart contracts enable direct funding. Contributors send BioT to project wallets, with funds locked until milestones (e.g., research results) are verified on-chain, ensuring accountability.

3.2 Uniswap V2 Liquidity

BioT trades on Uniswap V2 (pool: 0x07D322eFA22207F77aA0b8C6aEBf2A87035e0EE0) with 1.4M tokens, providing global liquidity and fast transactions via ETH pairing.

3.3 Transparency

Transactions are public on Etherscan (etherscan.io/token/0x7bC82B0775Bd344b1aC048b258b2d371Db5727a5), allowing real-time fund tracking.

3.4 Global Access

BioT is accessible via Ethereum wallets (e.g., MetaMask), enabling funding for researchers and investors worldwide.

3.5 Scalability

Ethereum supports BioT's transaction volume, with Layer-2 (e.g., Optimism) planned for Q2 2026 to reduce fees.

3.6 Community Governance

A staking contract by Q1 2026 will let BioT holders vote on funding proposals, ensuring user-driven growth.

4.0 Technical Architecture

BioT leverages Ethereum's security and compatibility:

4.1 Token Specifications

- Standard: ERC-20, compatible with wallets and DeFi.
- Contract Address: 0x7bC82B0775Bd344b1aC048b258b2d371Db5727a5.
- Security: Audited and verified on Etherscan, with a follow-up audit planned ($100-$300, Q1 2026).

4.2 Uniswap V2 Integration

- Pool Address: 0x07D322eFA22207F77aA0b8C6aEBf2A87035e0EE0.
- Details: 1.4M BioT tokens, 0.3% fee tier, ETH pair for stable trading.
- Strategy: Add tokens as adoption grows.

4.3 Transaction Process

- Funding: BioT sent to project wallets, locked until milestones are verified.
- Fees: 1% on funding transactions for platform maintenance.
- Verification: Etherscan tracks all transfers.

4.4 Future Upgrades

- Staking contract (Q1 2026) for voting.
- Layer-2 integration (Q2 2026) for lower fees.
- APIs (Q3 2026) for biotech platform integration.

5.0 Tokenomics

BioT's economics ensure transparency and sustainability:

5.1 Token Supply

- Total Supply: 485,000,000 tokens (fixed).
- Circulating Supply: 10,000,000 (June 2025, including 1.4M in pool).
- Contract Address: 0x7bC82B0775Bd344b1aC048b258b2d371Db5727a5.

5.2 Allocation

- 50% (242,500,000): Public sale via Uniswap.
- 30% (145,500,000): Development fund, locked until June 2027.
- 15% (72,750,000): Team, vested until June 2028.
- 5% (24,250,000): Marketing/partnerships, including $2,000 airdrop (1M tokens, Q3 2025).

5.3 Incentives

- Value Driver: Adoption for funding and trading.
- Fees: 1% on funding transactions for sustainability.
- Deflation: Potential token burn (Q4 2026, community vote).

5.4 Distribution

- Uniswap: 1.4M tokens in pool, more added as needed.
- Airdrop: $2,000 for 1M tokens in Q3 2025.
- Partnerships: 5% for biotech integrations.

6.0 Roadmap

BioT's development is streamlined into key phases:

- Q2 2025 (Completed): Launched BioT on Uniswap V2 (1.4M tokens), deployed audited ERC-20 contract (0x7bC82B0775Bd344b1aC048b258b2d371Db5727a5), began crypto forum outreach.
- Q3-Q4 2025: Secure CoinGecko/CoinMarketCap listings, launch website (Carrd, $0-$19), execute $2,000 airdrop (1M tokens), pursue CEX listings (e.g., DigiFinex, $15,000), engage biotech startups for pilots (500K tokens).
- Q1-Q2 2026: Deploy staking contract for voting, integrate Layer-2 (e.g., Optimism), conduct follow-up audit ($100-$300), launch pilot funding with partners (1M tokens).
- Q3 2026: Release APIs for biotech platforms, expand to more CEXs (e.g., BitMart, $40,000).

7.0 Team and Compliance

7.1 Team

Pseudonymous team:

- Lead Developer: 2+ years in Ethereum smart contract development.
- Project Coordinator: Biotech advocate for partnerships/outreach.
- Advisors: Seeking biotech experts (Q4 2025).

7.2 Compliance

- Security: Audited contract, follow-up audit (Q1 2026, $100-$300).
- KYC/AML: Exploring Sumsub ($100-$300) for CEXs.
- Transparency: Public transactions on Etherscan.
- Regulatory: Permissioned transactions by Q2 2026 for compliance.

8.0 Use Cases

8.1 Research Funding

Researchers receive BioT for projects, with funds locked until milestones are verified.

8.2 Startup Support

Startups raise capital via BioT campaigns, with transparent records.

8.3 Healthcare Crowdfunding

Fund diagnostics or therapies, tracked on-chain.

8.4 Data Sharing

Reward secure biotech data sharing with tokens.

9.0 Comparative Advantage

- Biotech Niche: Targets underserved funding needs.
- Liquidity: 1.4M tokens on Uniswap V2.
- Transparency: Etherscan-verified transactions.
- Scalability: Ethereum with Layer-2 plans.
- Governance: Community-driven staking.
- Compliance: Audited contract, KYC readiness.

10.0 Risks and Mitigation

- Volatility: Focus on utility, maintain liquidity.
- Regulation: Budget $100-$300 for KYC, permissioned contracts.
- Adoption: $2,000 airdrop, biotech partnerships.
- Security: Follow-up audit (Q1 2026).

11.0 Conclusion

BioT redefines biotech funding with Ethereum's blockchain, offering transparency and accessibility. With 485,000,000 tokens, 1.4M in Uniswap V2 (0x07D322eFA22207F77aA0b8C6aEBf2A87035e0EE0), and an audited contract (0x7bC82B0775Bd344b1aC048b258b2d371Db5727a5), BioT is poised for growth. Join the mission at Uniswap or contact ganda314@yahoo.com.